Psychopharmacological interventions in autism spectrum disorder (Q38739577)

6 September 2017

title

Psychopharmacological interventions in autism spectrum disorder (English)

1 reference

6 September 2017

main subject

autism spectrum disorder

0 references

0 references

Robert E Accordino

1 reference

6 September 2017

Christen Kidd

1 reference

6 September 2017

Laura C Politte

1 reference

6 September 2017

Charles A Henry

1 reference

6 September 2017

Christopher J McDougle

1 reference

6 September 2017

language of work or name

English

0 references

publication date

18 February 2016

1 reference

Expert Opinion on Pharmacotherapy

6 September 2017

1 reference

inferred from page(s)

published in

1 reference

6 September 2017

1 reference

6 September 2017

1 reference

6 September 2017

page(s)

937-952

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

6 September 2017

1 reference

The heavy burden of psychiatric comorbidity in youth with autism spectrum disorders: a large comparative study of a psychiatrically referred population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Autism spectrum disorders and health care expenditures: the effects of co-occurring conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Use of psychotropic medication in children and adolescents with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Association between depression and anxiety in high-functioning children with autism spectrum disorders and maternal mood symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Overrepresentation of mood and anxiety disorders in adults with autism and their first-degree relatives: what does it mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Depression and Anxiety Symptoms in Children and Adolescents with Autism Spectrum Disorders without Intellectual Disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Melatonin for insomnia in children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Melatonin for disordered sleep in individuals with autism spectrum disorders: systematic review and discussion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Early pharmacological treatment of autism: a rationale for developmental treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Validity of the aberrant behavior checklist in children with autism spectrum disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Risperidone in children with autism: randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Acute and long-term safety and tolerability of risperidone in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Olanzapine versus haloperidol in children with autistic disorder: an open pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Open-label study of olanzapine in children with pervasive developmental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Quetiapine in nine youths with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Open-label quetiapine in the treatment of children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Improvement in behaviour and attention in an autistic patient treated with ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Ziprasidone in adolescents with autism: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Case series: use of ziprasidone for maladaptive symptoms in youths with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Autism: electroencephalogram abnormalities and clinical improvement with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Levetiracetam in autistic children: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Oxcarbazepine in youths with autistic disorder and significant disruptive behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Brief report: retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Topiramate in children with autistic spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: case reports.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

N-acetylcysteine for major depressive episodes in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

A randomized controlled pilot trial of oral N-acetylcysteine in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Sulforaphane treatment of autism spectrum disorder (ASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Fluoxetine in autism with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Use of citalopram in pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

An open-label trial of escitalopram in pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

An Open-label Trial of Risperidone and Fluoxetine in Children with Autistic Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Clomipramine in Adults with Pervasive Developmental Disorders: A Prospective Open-Label Investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Clomipramine in autism: preliminary evidence of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

Differential response of seven subjects with autistic disorder to clomipramine and desipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1154536

10.1517/14656566.2016.1154536

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference